Gender differences in drug bioequivalence: Time to rethink practices

G. Koren; H. Nordeng; S. MacLeod

doi:10.1038/clpt.2012.233

Gender differences in drug bioequivalence: Time to rethink practices

G. Koren
, H. Nordeng
, S. MacLeod

نتاج البحث: نشر في مجلة › مقالة مرجعية › مراجعة النظراء

35 اقتباسات (Scopus)

ملخص

Currently, bioequivalence (BE) studies are carried out exclusively in males, assuming that intrasubject variabilities are similar between the sexes. This article challenges this hypothesis on the basis of available evidence and urges that studies of BE of sufficient power be undertaken in women also for all generic drugs aimed at women.

اللغة الأصلية	الإنجليزيّة
الصفحات (من إلى)	260-262
عدد الصفحات	3
دورية	Clinical Pharmacology and Therapeutics
مستوى الصوت	93
رقم الإصدار	3
المعرِّفات الرقمية للأشياء	https://doi.org/10.1038/clpt.2012.233
حالة النشر	نُشِر - مارس 2013
منشور خارجيًا	نعم

الوصول إلى المستند

10.1038/clpt.2012.233

الملفات والروابط الأخرى

Link to publication in Scopus

قم بذكر هذا

@article{a3addfee32d34fc0bcab48c1e4a686c3,

title = "Gender differences in drug bioequivalence: Time to rethink practices",

abstract = "Currently, bioequivalence (BE) studies are carried out exclusively in males, assuming that intrasubject variabilities are similar between the sexes. This article challenges this hypothesis on the basis of available evidence and urges that studies of BE of sufficient power be undertaken in women also for all generic drugs aimed at women.",

author = "G. Koren and H. Nordeng and S. MacLeod",

year = "2013",

month = mar,

doi = "10.1038/clpt.2012.233",

language = "אנגלית",

volume = "93",

pages = "260--262",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "Wiley-Blackwell",

number = "3",

}

TY - JOUR

T1 - Gender differences in drug bioequivalence

T2 - Time to rethink practices

AU - Koren, G.

AU - Nordeng, H.

AU - MacLeod, S.

PY - 2013/3

Y1 - 2013/3

N2 - Currently, bioequivalence (BE) studies are carried out exclusively in males, assuming that intrasubject variabilities are similar between the sexes. This article challenges this hypothesis on the basis of available evidence and urges that studies of BE of sufficient power be undertaken in women also for all generic drugs aimed at women.

AB - Currently, bioequivalence (BE) studies are carried out exclusively in males, assuming that intrasubject variabilities are similar between the sexes. This article challenges this hypothesis on the basis of available evidence and urges that studies of BE of sufficient power be undertaken in women also for all generic drugs aimed at women.

UR - https://www.scopus.com/pages/publications/84874188816

U2 - 10.1038/clpt.2012.233

DO - 10.1038/clpt.2012.233

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

C2 - 23299647

AN - SCOPUS:84874188816

SN - 0009-9236

VL - 93

SP - 260

EP - 262

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

IS - 3

ER -

Gender differences in drug bioequivalence: Time to rethink practices

ملخص

الوصول إلى المستند

الملفات والروابط الأخرى

بصمة

قم بذكر هذا